Systemic mastocytosis

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

7 regimens on this page 13 variants on this page

Aggressive systemic mastocytosis (ASM)

Cladribine (Leustatin)

back to top

Regimen #1

Study	Evidence
Kluin-Nelemans et al. 2003	Pilot, <20 patients reported

Chemotherapy

• Cladribine (Leustatin) 0.13 mg/kg IV over 2 hours once per day on days 1 to 5

Supportive medications

• Clemastine (Tavist) 1 to 2 mg IV prior to Cladribine (Leustatin)
• Dexamethasone (Decadron) 5 mg IV prior to Cladribine (Leustatin)
• Fluconazole (Diflucan) (dose not specified)
• Co-trimaxazole (dose not specified)
• Valacyclovir (Valtrex) (dose not specified) "in some patients"

4 to 6-week cycle for 6 cycles

Regimen #2

Study	Evidence
Lim et al. 2009	Retrospective

This is a retrospective series.

Chemotherapy

• Cladribine (Leustatin) 5 mg/m² or 0.13 to 0.17 mg/kg IV over 2 hours once per day on days 1 to 5

Median number of treatment cycles was 3 (range 1 to 9)

Regimen #3

Study	Evidence
Hermine et al. 2010	Non-randomized

This is the largest series but is published in abstract only.

Chemotherapy

• Cladribine (Leustatin) 0.15 mg/kg IV over 2 hours or SC once per day on days 1 to 5

4 to 12-week cycle for 1 to 6 cycles

References

1. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood. 2003 Dec 15;102(13):4270-6. Epub 2003 Aug 21. link to original article contains verified protocol PubMed
2. Retrospective: Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. link to original article PubMed
3. Abstract: Hermine, Olivier, Hirsh, Isabelle, Damaj, Gandhi, Granpeix, Catherine, Barete, Stephane, Suarez, Felipe, Chansderis, Olivia, Ghez, David, Delarue, Richard, Lanternier, Fanny, Deau, Benedicte, Coignard, Helene, Fraitag, Sylvie, Canioni, Danielle, Casassus, Philippe, Dubreuil, Patrice, Lortholary, Olivier. Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. ASH Annual Meeting Abstracts 2010 116: 1982 link to original abstract

Dasatinib (Sprycel)

back to top

Regimen

Study	Evidence
Verstovsek et al. 2008	Phase II

Only 9 of 67 patients studied had ASM; 18 has ISM and 6 had SM-AHNMD.

Chemotherapy

• Dasatinib (Sprycel) 70 mg PO BID or 140 mg PO once per day

Supportive medications

• Hematopoietic growth factors at investigator discretion

28-day cycles until disease progression or intolerable toxicity

References

1. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15;14(12):3906-15. link to original article contains verified protocol PubMed

Imatinib (Gleevec)

back to top

Regimen #1

Study	Evidence
Vega-Ruiz et al. 2009	Phase II

Chemotherapy

• Imatinib (Gleevec) 400 mg PO once per day, increased by 200 mg every month to a maximum of 800 mg PO once per day

Supportive medications

• Hematopoietic growth factors at investigator discretion

Continued until disease progression or unacceptable toxicity.

Regimen #2

Study	Evidence
Droogendijk et al. 2006	Phase II, <20 patients reported

Chemotherapy

• Imatinib (Gleevec) 400 mg PO once per day

Supportive medications

• Prednisone (Sterapred) 15 mg PO BID for first 2 weeks of treatment

Up to 6 month course

References

1. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet. 2003 Aug 16;362(9383):535-6. link to original article PubMed
2. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. link to original article contains verified protocol PubMed
3. Retrospective: Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol. 2008 Dec;88(5):483-8. Epub 2008 Nov 26. link to original article PubMed
4. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009 Nov;33(11):1481-4. Epub 2009 Feb 3. link to original article contains verified protocol PubMed
5. Retrospective: Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009 Dec;84(12):790-4. link to original article PubMed